. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Oral Dis. 2020 Dec 14;28(1):193–201. doi: 10.1111/odi.13746

Table 3.

Genetic Associations with ONJ

Gene	rsID	Odds Ratio	95% Confidence Interval	P-Value	Adjusted^* Odds Ratio	95% Confidence Interval	P-Value
CYP2C8	rs1934951^**	0.960	0.548–1.682	0.89
	rs1341162	0.913	0.505–1.651	0.76
	rs1934980	0.911	0.473–1.754	0.78
PPARG	rs1152003	1.898	1.093–3.297	0.02	1.918	0.996–3.692	0.05
VEGFC	rs7664413	3.222	1.324–7.844	0.01	4.078	1.292–12.873	0.02
	rs2333496	0.516	0.273–0.973	0.04	0.542	0.257–1.141	0.11
	rs6838834	2.000	0.518–7.718	0.31
	rs3775203	1.245	0.646–2.397	0.51
VEGFA	rs833061	1.995	0.974–4.087	0.06
	rs699947	1.407	0.767–2.583	0.27
	rs2010963	1.347	0.677–2.683	0.40
FDPS	rs11264359	0.788	0.417–1.489	0.46
FDPS	rs17367421	2.253	0.336–15.112	0.40
IGFBP7	rs11934877	1.310	0.642–2.672	0.46
ABCC4	rs1678387	0.757	0.212–2.701	0.67

Significant associations in the univariate analysis were adjusted for Bevacizumab and Bisphosphonate

^**

Pre-specified primary SNP analysis

Bold indicates statistical significance (p<0.05)